Literature DB >> 20107018

Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes.

Udayan Chatterji1, Michael D Bobardt, Precious Lim, Philippe A Gallay.   

Abstract

The mechanisms by which cyclophilin A (CypA) governs hepatitis C virus (HCV) replication remain unknown. Since CypA binds two essential components of the HCV replication complex (RC)--the polymerase NS5B and the phosphoprotein NS5A--we asked in this study whether CypA regulates their RC association. We found that CypA, via its isomerase pocket, locates in a protease-resistant compartment similar to that where HCV replicates. CypA association with this compartment is not mediated by HCV. Moreover, CypA depletion of RC does not influence NS5A and NS5B RC association, arguing against a model where CypA governs HCV replication by recruiting NS5A or NS5B into RC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20107018      PMCID: PMC2888154          DOI: 10.1099/vir.0.018531-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  28 in total

1.  Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

Authors:  Koichi Watashi; Naoto Ishii; Makoto Hijikata; Daisuke Inoue; Takayuki Murata; Yusuke Miyanari; Kunitada Shimotohno
Journal:  Mol Cell       Date:  2005-07-01       Impact factor: 17.970

2.  Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.

Authors:  Feng Yang; Jason M Robotham; Heather B Nelson; Andre Irsigler; Rachael Kenworthy; Hengli Tang
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

Review 3.  Cyclophilin inhibitors.

Authors:  Philippe A Gallay
Journal:  Clin Liver Dis       Date:  2009-08       Impact factor: 6.126

4.  Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition.

Authors:  L D Zydowsky; F A Etzkorn; H Y Chang; S B Ferguson; L A Stolz; S I Ho; C T Walsh
Journal:  Protein Sci       Date:  1992-09       Impact factor: 6.725

5.  Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.

Authors:  Kaku Goto; Koichi Watashi; Daisuke Inoue; Makoto Hijikata; Kunitada Shimotohno
Journal:  Cancer Sci       Date:  2009-06-26       Impact factor: 6.716

6.  Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins.

Authors:  G Fischer; B Wittmann-Liebold; K Lang; T Kiefhaber; F X Schmid
Journal:  Nature       Date:  1989-02-02       Impact factor: 49.962

7.  Effects of viral chemotherapeutic agents on membrane properties. Studies of cyclosporin A, benzyloxycarbonyl-D-Phe-L-Phe-Gly and amantadine.

Authors:  R M Epand; R F Epand; R C McKenzie
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

8.  The isomerase active site of cyclophilin A is critical for hepatitis C virus replication.

Authors:  Udayan Chatterji; Michael Bobardt; Suganya Selvarajah; Feng Yang; Hengli Tang; Noayo Sakamoto; Gregoire Vuagniaux; Tanya Parkinson; Philippe Gallay
Journal:  J Biol Chem       Date:  2009-04-20       Impact factor: 5.157

9.  Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.

Authors:  Joanna E Mathy; Sue Ma; Teresa Compton; Kai Lin
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

10.  Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.

Authors:  Lotte Coelmont; Suzanne Kaptein; Jan Paeshuyse; Inge Vliegen; Jean-Maurice Dumont; Grégoire Vuagniaux; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

View more
  19 in total

1.  Differential loss of prolyl isomerase or chaperone activity of Ran-binding protein 2 (Ranbp2) unveils distinct physiological roles of its cyclophilin domain in proteostasis.

Authors:  Kyoung-in Cho; Hemangi Patil; Eugene Senda; Jessica Wang; Haiqing Yi; Sunny Qiu; Dosuk Yoon; Minzhong Yu; Andrew Orry; Neal S Peachey; Paulo A Ferreira
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

Review 2.  Anti-HCV drugs in the pipeline.

Authors:  Priscilla L Yang; Min Gao; Kai Lin; Qingsong Liu; Valerie A Villareal
Journal:  Curr Opin Virol       Date:  2011-11-13       Impact factor: 7.090

Review 3.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

Review 4.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

Review 5.  Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.

Authors:  Sheng-Shun Yang; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2015-11-05       Impact factor: 6.047

Review 6.  Development of novel antiviral therapies for hepatitis C virus.

Authors:  Kai Lin
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

7.  Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.

Authors:  Dries Verdegem; Aurélie Badillo; Jean-Michel Wieruszeski; Isabelle Landrieu; Arnaud Leroy; Ralf Bartenschlager; François Penin; Guy Lippens; Xavier Hanoulle
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

8.  Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.

Authors:  Udayan Chatterji; Michael Bobardt; Andrew Tai; Malcolm Wood; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

9.  Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A.

Authors:  Claire Rosnoblet; Bernd Fritzinger; Dominique Legrand; Hélène Launay; Jean-Michel Wieruszeski; Guy Lippens; Xavier Hanoulle
Journal:  J Biol Chem       Date:  2012-11-14       Impact factor: 5.157

Review 10.  Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.

Authors:  Precious J Lim; Philippe A Gallay
Journal:  Curr Opin Virol       Date:  2014-05-27       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.